SAN DIEGO, Feb. 13, 2020 /PRNewswire/ –NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the results of the study, “Prone single-position extreme lateral interbody fusion (pro-XLIF): preliminary results,” in The European Spine Journal, validating the versatility of NuVasive’s MaXcess® retractor in prone, single-position eXtreme Lateral Interbody Fusion (XLIF®) and posterior fixation.
“This study describes the surgical technique for and presents early clinical validation of an evolutionary approach to NuVasive’s flagship XLIF procedure,” said Kyle Malone, vice president of medical, clinical, and regulatory affairs at NuVasive. “The results build on prior literature validation of our X360 lateral single-position surgery system and shows the versatility of the MaXcess retractor’s ability to perform single-position XLIF in a number of patient positions. Furthermore, the published study underscores the continued commitment of thought leaders, including study authors Prof. Lamartina and Dr. Berjano, to advance techniques in lateral approach surgery.”
In this prospective, comparative study, perioperative outcomes were compared between a consecutive series of prone single-position XLIF with posterior fixation patients (pro-XLIF) and patients treated with XLIF in the lateral position who were then repositioned prone for posterior fixation. The authors found no major complications in either group. While average pro-XLIF patient preparation and fluoroscopy times were slightly longer than in XLIF patients, the overall procedure time was nearly 50 minutes shorter for the single-position XLIF patients. Disability and pain improvements were similar between the groups. All patients in this study were treated with XLIF using the MaXcess retractor, a key tool in the Company’s X360™ system, a comprehensive approach to lateral single-position surgery leveraging advanced techniques and technologies to deliver best-in-class, patient-specific care, while enhancing operating room workflow and efficiency.
“Pro-XLIF provides an opportunity for surgeons who feel more comfortable with the traditional prone position to incorporate the advantages of both XLIF and single-position surgery in select patients,” said Dr. Pedro Berjano, orthopedic spine surgeon at IRCCS Istituto Ortopedico Galleazzi in Milan, Italy. “For those facing complex deformity and revision cases, pro-XLIF may allow for a wider range of posterior corrective maneuvers with the patient in the prone position with enhanced intraoperative efficiency and reduced operative time for the patient.”
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenue, NuVasive has approximately 2,800 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.